Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS): 3 Ana
Post# of 29735
Posted On: 10/23/2015 9:17:25 AM
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS): 3 Analyst have given the stock of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) a near short term price target of $1.83. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $0.29. The higher price target estimate is at $2 while the lower price estimates are fixed at $2.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has received a short term rating of hold from research analysts at Zacks with a rank of 3. The company has been rated an average of 3 by 4 Wall Street Analysts. 4 analysts have advised hold.
Currently the company Insiders own 14.6% of Sunesis Pharmaceuticals, Inc. shares according to the proxy statements. Institutional Investors own 58.26% of Sunesis Pharmaceuticals, Inc. shares. Many analysts have commented on the company rating. In a research note released to the investors, Cowen & Company downgrades its rating on Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS).The analysts at the brokerage house have a current rating of Market Perform on the shares. Earlier, the shares were rated a Outperform by the brokerage firm. The rating by the firm was issued on July 24, 2015.
On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, Swisher Daniel N Jr, CEO of Sunesis Pharmaceuticals Inc, executed a transaction worth $25,250 on August 24, 2015. A total of 25,000 shares were purchased at an average price of $1.01. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) : On Thursday heightened volatility was witnessed in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) which led to swings in the share price. The shares opened for trading at $0.84 and hit $0.919 on the upside , eventually ending the session at $0.9175, with a gain of 9.23% or 0.0775 points. The heightened volatility saw the trading volume jump to 398,573 shares. The 52-week high of the share price is $3.72 and the company has a market cap of $69 million. The 52-week low of the share price is at $0.7416 .
Sunesis Pharmaceuticals, Inc. has lost 7.58% in the last five trading days and dropped 18.08% in the last 4 weeks. Sunesis Pharmaceuticals, Inc. has dropped 4.33% during the last 3-month period . Year-to-Date the stock performance stands at -64.02%.
Sunesis Pharmaceuticals, Inc. (Sunesis) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The Company is focuses primarily on the development of vosaroxin for the treatment of acute myeloid leukemia (AML). Vosaroxin is a anti-cancer quinolone derivative (AQD). AQDs have been shown to mediate anti-tumor activity by targeting mammalian topoisomerase II, an enzyme critical for cell replication. The Company owns worldwide development and commercialization rights to vosaroxin. The Companys VALOR trial is designed to evaluate the effect of vosaroxin in combination with cytarabine, chemotherapy in AML. The trial has an adaptive design and is based on data from the Companys Phase II clinical trial of vosaroxin in combination with cytarabine in relapsed or refractory AML.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has received a short term rating of hold from research analysts at Zacks with a rank of 3. The company has been rated an average of 3 by 4 Wall Street Analysts. 4 analysts have advised hold.
Currently the company Insiders own 14.6% of Sunesis Pharmaceuticals, Inc. shares according to the proxy statements. Institutional Investors own 58.26% of Sunesis Pharmaceuticals, Inc. shares. Many analysts have commented on the company rating. In a research note released to the investors, Cowen & Company downgrades its rating on Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS).The analysts at the brokerage house have a current rating of Market Perform on the shares. Earlier, the shares were rated a Outperform by the brokerage firm. The rating by the firm was issued on July 24, 2015.
On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, Swisher Daniel N Jr, CEO of Sunesis Pharmaceuticals Inc, executed a transaction worth $25,250 on August 24, 2015. A total of 25,000 shares were purchased at an average price of $1.01. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) : On Thursday heightened volatility was witnessed in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) which led to swings in the share price. The shares opened for trading at $0.84 and hit $0.919 on the upside , eventually ending the session at $0.9175, with a gain of 9.23% or 0.0775 points. The heightened volatility saw the trading volume jump to 398,573 shares. The 52-week high of the share price is $3.72 and the company has a market cap of $69 million. The 52-week low of the share price is at $0.7416 .
Sunesis Pharmaceuticals, Inc. has lost 7.58% in the last five trading days and dropped 18.08% in the last 4 weeks. Sunesis Pharmaceuticals, Inc. has dropped 4.33% during the last 3-month period . Year-to-Date the stock performance stands at -64.02%.
Sunesis Pharmaceuticals, Inc. (Sunesis) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The Company is focuses primarily on the development of vosaroxin for the treatment of acute myeloid leukemia (AML). Vosaroxin is a anti-cancer quinolone derivative (AQD). AQDs have been shown to mediate anti-tumor activity by targeting mammalian topoisomerase II, an enzyme critical for cell replication. The Company owns worldwide development and commercialization rights to vosaroxin. The Companys VALOR trial is designed to evaluate the effect of vosaroxin in combination with cytarabine, chemotherapy in AML. The trial has an adaptive design and is based on data from the Companys Phase II clinical trial of vosaroxin in combination with cytarabine in relapsed or refractory AML.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼